Biomarkers for Oncology
JH · Effective Oct 1, 2015
84 active Medicare policies list D46.9, and 10 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J5 · Effective Oct 1, 2015
J8 · Effective Oct 1, 2015
J15 · Effective Oct 1, 2015
J6 · Effective Aug 1, 2018
JK · Effective Aug 1, 2018
J6 · Effective Oct 1, 2015
10 policies from 4 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of D46.9 |
|---|---|---|
| Flow Cytometry, Ektacytometry, DNA Ploidy, and S-phase Fraction | Jun 5, 2023 | Covered |
| Genetic Testing | Feb 27, 2024 | Covered |
| Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) | Feb 20, 2024 | Covered |
| Pharmacogenetic and Pharmacodynamic Testing | Feb 27, 2024 | Covered |
| Romiplostim (Nplate) | Jan 9, 2024 | Covered |
| Tumor Markers | Mar 5, 2024 | Covered |
JK · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JE · Effective Aug 8, 2022
JF · Effective Aug 8, 2022
JJ · Effective Jul 3, 2022
JM · Effective Jul 3, 2022
J5 · Effective Jul 3, 2022
J8 · Effective Jul 3, 2022
J15 · Effective Dec 26, 2021
JE · Effective Jan 2, 2022
JF · Effective Jan 2, 2022
JJ · Effective Dec 26, 2021
JM · Effective Dec 26, 2021
J5 · Effective Dec 26, 2021
J8 · Effective Dec 26, 2021
J15 · Effective Feb 10, 2020
JE · Effective May 17, 2020
JF · Effective May 17, 2020
JJ · Effective Feb 10, 2020
JM · Effective Feb 10, 2020
J5 · Effective Feb 9, 2020
J8 · Effective Feb 9, 2020
JE · Effective Aug 17, 2025
JF · Effective Aug 17, 2025
JJ · Effective Aug 17, 2025
JM · Effective Aug 17, 2025
J5 · Effective Aug 17, 2025
J8 · Effective Aug 17, 2025
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
J9 · Effective Oct 1, 2015
J6 · Effective May 1, 2017
JK · Effective May 1, 2017
JJ · Effective Jun 12, 2017
JM · Effective Jun 12, 2017
JL · Effective Apr 24, 2025
National · Effective Oct 1, 2026
J5 · Effective Apr 1, 2025
National · Effective Mar 5, 2026
J6 · Effective Apr 1, 2026
J6 · Effective Apr 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Aug 6, 2026
National · Effective Aug 13, 2026
J5 · Effective Aug 6, 2026
National · Effective Apr 24, 2025
National · Effective Feb 5, 2026
National · Effective Apr 24, 2025
J5 · Effective Apr 24, 2025
National · Effective Oct 1, 2026
National · Effective Sep 24, 2026
J5 · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 12, 2026
National · Effective Oct 12, 2026
National · Effective Oct 12, 2026
National · Effective Oct 12, 2026
National · Effective Nov 20, 2025
National · Effective Feb 5, 2026
J5 · Effective Nov 20, 2025
J6 · Effective Jul 15, 2026
J6 · Effective Apr 1, 2026
National · Effective Oct 30, 2025
National · Effective Jul 1, 2026
National · Effective Oct 1, 2026
| Policy | Effective | Status of D46.9 |
|---|---|---|
| Concert Genetic Testing Oncology: Hematologic Malignancy | Not recorded | Referenced |
| Concert Genetic Testing: Hematology | Not recorded | Referenced |
| Policy | Effective | Status of D46.9 |
|---|---|---|
| Cellular Therapy Products for Allogeneic Stem Cell Transplantation | Oct 1, 2026 | Covered |
| Policy | Effective | Status of D46.9 |
|---|---|---|
| Serum Folate and Red Blood Cell Folate Testing | Dec 15, 2025 | Covered |